UCB’s Vimpat gets NHS green light in Wales
The All Wales Medicines Strategy Group has approved NHS funding for the use of UCB’s Vimpat in children with epilepsy.
Read More
Tag: lacosamide
EU allows use of UCB’s anti-epileptic Vimpat in children
The European Commission has ruled that UCB’s anti-epileptic Vimpat can be used in children.
Read More
Eleven medicines leap closer to EU approval
Eleven therapies, including five targeting rare diseases, have taken a giant leap towards being approved in Europe after winning backing from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
UCB bags key US patent win
UCB has secured an important win for the protection of its anti-epileptic Vimpat in the US this week after the Delaware District Court confirmed the validity of a key patent for the drug.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
